![Patients With Prior Myocardial Infarction, Stroke, or Symptomatic Peripheral Arterial Disease in the CHARISMA Trial - ScienceDirect Patients With Prior Myocardial Infarction, Stroke, or Symptomatic Peripheral Arterial Disease in the CHARISMA Trial - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0735109707009928-gr3.jpg)
Patients With Prior Myocardial Infarction, Stroke, or Symptomatic Peripheral Arterial Disease in the CHARISMA Trial - ScienceDirect
![Pharmacology in Acute Coronary Syndromes: Anti-platelet Agents Tim Kinnaird, University Hospital Wales, Cardiff and Vale NHS Trust. - ppt download Pharmacology in Acute Coronary Syndromes: Anti-platelet Agents Tim Kinnaird, University Hospital Wales, Cardiff and Vale NHS Trust. - ppt download](https://images.slideplayer.com/15/4583024/slides/slide_11.jpg)
Pharmacology in Acute Coronary Syndromes: Anti-platelet Agents Tim Kinnaird, University Hospital Wales, Cardiff and Vale NHS Trust. - ppt download
![Patients With Prior Myocardial Infarction, Stroke, or Symptomatic Peripheral Arterial Disease in the CHARISMA Trial - ScienceDirect Patients With Prior Myocardial Infarction, Stroke, or Symptomatic Peripheral Arterial Disease in the CHARISMA Trial - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0735109707009928-gr1.jpg)
Patients With Prior Myocardial Infarction, Stroke, or Symptomatic Peripheral Arterial Disease in the CHARISMA Trial - ScienceDirect
![Application of the Academic Research Consortium High Bleeding Risk Criteria in an All-Comers Registry of Percutaneous Coronary Intervention | Circulation: Cardiovascular Interventions Application of the Academic Research Consortium High Bleeding Risk Criteria in an All-Comers Registry of Percutaneous Coronary Intervention | Circulation: Cardiovascular Interventions](https://www.ahajournals.org/cms/asset/52f9973d-b804-4188-86b8-0ab390822191/e008307fig06.jpg)
Application of the Academic Research Consortium High Bleeding Risk Criteria in an All-Comers Registry of Percutaneous Coronary Intervention | Circulation: Cardiovascular Interventions
![C.R.E.D.O. C lopidogrel for the R eduction of E vents D uring O bservation Multicenter Multinational (USA, Canada) Prospective Randomized Double Blind. - ppt download C.R.E.D.O. C lopidogrel for the R eduction of E vents D uring O bservation Multicenter Multinational (USA, Canada) Prospective Randomized Double Blind. - ppt download](https://images.slideplayer.com/24/7043962/slides/slide_23.jpg)
C.R.E.D.O. C lopidogrel for the R eduction of E vents D uring O bservation Multicenter Multinational (USA, Canada) Prospective Randomized Double Blind. - ppt download
![Triple therapy: A review of antithrombotic treatment for patients with atrial fibrillation undergoing percutaneous coronary intervention - Journal of Cardiology Triple therapy: A review of antithrombotic treatment for patients with atrial fibrillation undergoing percutaneous coronary intervention - Journal of Cardiology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/37341bb4-e97f-43e5-9e52-520b2e6d2aba/gr2_lrg.jpg)
Triple therapy: A review of antithrombotic treatment for patients with atrial fibrillation undergoing percutaneous coronary intervention - Journal of Cardiology
Meta-Analysis of the Efficacy and Safety of Clopidogrel Plus Aspirin as Compared to Antiplatelet Monotherapy for the Prevention
![Prevalence of Chronic Kidney Disease in Type 2 Diabetes: The Canadian REgistry of Chronic Kidney Disease in Diabetes Outcomes (CREDO) Study - Clinical Therapeutics Prevalence of Chronic Kidney Disease in Type 2 Diabetes: The Canadian REgistry of Chronic Kidney Disease in Diabetes Outcomes (CREDO) Study - Clinical Therapeutics](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/5fe49eab-4e2e-423e-b65e-e64c75c18a51/gr1_lrg.jpg)
Prevalence of Chronic Kidney Disease in Type 2 Diabetes: The Canadian REgistry of Chronic Kidney Disease in Diabetes Outcomes (CREDO) Study - Clinical Therapeutics
![8 European countries, 48 centres Stent implantation Double-blind randomisation n = 1005 Clopidogrel 300mg od Aspirin 325mg od Clopidogrel 75mg od Aspirin. - ppt download 8 European countries, 48 centres Stent implantation Double-blind randomisation n = 1005 Clopidogrel 300mg od Aspirin 325mg od Clopidogrel 75mg od Aspirin. - ppt download](https://images.slideplayer.com/28/9367816/slides/slide_4.jpg)
8 European countries, 48 centres Stent implantation Double-blind randomisation n = 1005 Clopidogrel 300mg od Aspirin 325mg od Clopidogrel 75mg od Aspirin. - ppt download
![Figure 1 from Interpreting the CHARISMA study. What is the role of dual antiplatelet therapy with clopidogrel and aspirin? | Semantic Scholar Figure 1 from Interpreting the CHARISMA study. What is the role of dual antiplatelet therapy with clopidogrel and aspirin? | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/414c93040a02611cf8f4fe89758858f025cbe64c/4-Figure1-1.png)
Figure 1 from Interpreting the CHARISMA study. What is the role of dual antiplatelet therapy with clopidogrel and aspirin? | Semantic Scholar
![PPT - Early And Long Term Treatment With Clopidogrel In Coronary Artery Disease PowerPoint Presentation - ID:475326 PPT - Early And Long Term Treatment With Clopidogrel In Coronary Artery Disease PowerPoint Presentation - ID:475326](https://image.slideserve.com/475326/overall-study-design-credo-l.jpg)